BRAF V600E mutations are common in different tumor ... are currently utilized for the therapy of malignant metastatic melanoma. They include RAF inhibitors, such as sorafenib and vemurafenib ...

V600E is the most commonly encountered BRAF mutation. Braftovi – which Pfizer ... for unresectable or metastatic BRAF-positive melanoma and non-small cell lung cancer (NSCLC), and as a second ...

Patients presenting these mutations ... in our BRAF V600E models. BRAF inhibitors have revolutionized the treatment of BRAF-mutated metastatic colorectal cancer or melanoma, while KRAS inhibitors ...

Challenges in patient selection for surgical options in V600E BRAF–mutated metastatic colorectal cancer.

FDA approved for the treatment of metastatic melanoma harboring activating BRAF mutations in August, 2011. Vemurafenib is metabolized by cytochrome P450 isoenzymes (predominantly CYP3A4 ...

Braftovi is a small molecule inhibitor of proteins with the BRAF V600E mutation, which can lead ... in 2018 as a treatment for advanced cases of melanoma. It has since been approved as a second ...

Can you do it? Can you ace these quiz questions about BRAF V600E mutations? They’re all derived from the current literature. At the end of the quiz, compare your score with those of your ...

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials ...

"The BRAFTOVI regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with mCRC with a BRAF V600E mutation. We look forward ...